Volume 4, Issue 1, March 2020, Page: 18-23
Therapeutic Itinerary of the Patients Followed for Myasthenia Gravis in Dakar
Kaba Yacouba, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Mourabit Salaheddine, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Atsa Kouda Daniel, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Affognon Cadnelle Christelle, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Bugeme Marcellin, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Fall Maouly, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Pikine National Hospital, Dakar-Senegal
Seck Lala Bouna, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Ndiaye Moustapha, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Diop Gallo Amadou, Neurology Department, Faculty of Medicine, Pharmacy and Dentistry of the Sheikh Anta Diop University of Dakar, Neurosciences Clinic I. P Ndiaye – Fann National University Hospital Center, Dakar-Senegal
Received: Jun. 19, 2019;       Accepted: Feb. 6, 2020;       Published: Feb. 14, 2020
DOI: 10.11648/j.cnn.20200401.14      View  321      Downloads  114
Abstract
Introduction: Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that induce dysfunction of neuromuscular transmission. The diagnostic procedure is similar regardless of the age of the subject. As in any disease, the management starts with the diagnosis, which is often unduly delayed. The purpose of our study was to evaluate the reasons for this delay. Methodology: This was a retrospective, transversal, and descriptive study on the files of myasthenic subjects followed over a period of four years (2014 to 2017) at the neuroscience clinic of the Univresity National Center of Fann and at the consultation of neurology of the Pikine National Hospital Center where a hetero-administered questionnaire was completed. Results: The study involved 18 myasthenic patients including 13 women and 5 men with a sex ratio of 2.6. The median age of the patients was 32 years [14 - 60 years]. The average time to patient diagnosis was 24 months. The patients had consulted on average four times before the diagnosis of myasthenia gravis. The referral hospital was the facility attended by 78% of patients and the ophthalmology service was the first service consulted by 13 patients, or 72%. The median age at onset of symptoms was 28 years. Ptosis was the first symptom in 56% of the cases. Conclusion: Myasthenia gravis is a disorder little known to the public and to practitioners. The ophthalmologist was the first remedy. It would be wise for any practitioner to know the main manifestations.
Keywords
Myasthenia Gravis, Therapeutic Itinerary, Dakar
To cite this article
Kaba Yacouba, Mourabit Salaheddine, Atsa Kouda Daniel, Affognon Cadnelle Christelle, Bugeme Marcellin, Fall Maouly, Seck Lala Bouna, Ndiaye Moustapha, Diop Gallo Amadou, Therapeutic Itinerary of the Patients Followed for Myasthenia Gravis in Dakar, Clinical Neurology and Neuroscience. Vol. 4, No. 1, 2020, pp. 18-23. doi: 10.11648/j.cnn.20200401.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
B. Eymard. La myasthénie pour l’interniste. Revue Neurologie. 2014; A200–02.
[2]
A. El Midaoui, O. Messouak, M. F. Belahsen. La myasthénie. Amether. 2010; 2 (1): 54–65.
[3]
S. Berrih-Aknin, R. Le Panse. Myasthénie et auto-anticorps: physiopathologie des différentes entités. La Revue de médecine interne. 2014; 35: 413–420.
[4]
H. Holtsema, J. Mourik, R. E. Rico, J. R. Falconi, J. B. M. Kuks, H. J. G. H. Oosterhuis. Myasthenia gravis on the Dutch Antilles: an epidemiological study. Clinical Neurology and Neurosurgery. 2001; 102 (4): 195-8.
[5]
K. J. Bateman et al. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S Afr Med J. 2007; 97 (10): 959-62.
[6]
A. Saraux-Bonneton, B. Raffin, F. Vautier, J. Laudet. Myasthénie et personnes âgées. À partir d’une observation. Rev Méd Interne. 2001; 22: 984-7.
[7]
F. Durand, J. P. Camdessanché, L. Jomir, J. C. Antoine, P. Cathébras. Myasthénie du sujet âgé: analyse rétrospective de 23 observations. Revue Médecine interne. 2005; 26: 924–930.
[8]
R. Beekman, J. B. M. Kuks, H. J. G. M. Oosterhuis. Myasthenia gravis: Diagnostic and follow-up of 100 consecutive patients. J. Neurol. 1997; 244: 112-8.
[9]
A. S. Carr et al. Systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010; 10: 46.
[10]
W. B. P. Matuja et al. Incidence and characteristics of myasthenia gravis in Dar Es Salaam, Tanzania. East African Medical Journal. 2001; 78 (9): 473-76.
[11]
M. A. Hellmann, R. Mosberg-galili, I. Steiner. Myasthenia gravis in the elderly. J. Neurol Sci. 2013; 325: 1–5.
[12]
A. Meyer, Y. Levy. Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews. 2010; 9: A383–86.
[13]
A. U. Wing Lok et al. MMed FAMS. Myasthenia gravis in Singapore. Neurol J Southeast Asia. 2003; 8: 35–40.
[14]
B. S. Singhal et al. Myasthenia gravis: A study from India. Neurol India. 2008; 56 (3): 352-55.
[15]
R. Mantegazza et al. Myasthénie grave: données épidémiologiques et facteurs pronostiques. Am. Acad. Sciences de NY. 2003; 998 (1): 413-23.
[16]
D. Lavrnic et al. Epidemiological and clinical characteristics of myasthenia gravis in Belgrade Yugoslavia. Acta Neurol Scand. 1999; 100: 168-174.
[17]
X. Zhang et al. Clinical and serological study of myasthenia gravis in HuBei Provi China. J Neurol Neurosurg Psychiatry. 2007; 78 (4): 386-90.
[18]
H. S. Roh, S. Lee, J. S. Yoon. Comparaison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis. Korean J Ophthalmol. 2011; 25 (1): 1-7.
[19]
R. Ohta, M. Motomura, B. Rinsho. Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis. Rinsho Byori. 2014; 62 (3): 255-260.
[20]
S. J. OH et al. Racial differences in myasthenia gravis in Alabama. Muscle Nerve. 2009 Mar; 39 (3): 328-332.
[21]
M. Garcia-carrasco et al. Therapeutic options in autoimmune myasthenia gravis. Autoimmunity Reviews. 2007; 6: 373–378.
[22]
M. Meriggioli, D. Sanders. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8: 475–88.
[23]
C. Schneider-Gold et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005 (2).
Browse journals by subject